Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer: A phase I study

Tumori

Volumn 88, Issue 2, 2002, Pages 99-103

  Frassineti, Giovanni Luca ^a   Ibrahim, Toni ^a   Zoli, Wainer ^a   Monti, Manuela ^a   Ricotti, Luca ^a   Nanni, Oriana ^a   Amadori, Dino ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Docetaxel; Gemcitabine; Non small cell lung cancer

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; TOXICITY; VOMITING;

EID: 0036269173     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800204     Document Type: Article

References (28)

1. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
2. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
3. Phase I study of docexatel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
4. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer
5. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
6. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial
7. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
8. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced NSCLC: A randomized phase III study of the Italian Lung Cancer Project
9. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
10. Gemcitabine - A safety review
11. Single agents in the second-line treatment of nonsmall cell lung cancer
12. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer
13. Gemcitabine as secondline treatment for advanced non-small cell lung cancer: A phase II trial
14. Phase II study of docetaxel for advanced or metastatic platinum-refractory NSCLC
15. Activity of gemcitabine in patients with NSCLC: A multicentre, extended phase II study
16. Single agent docetaxel plus granulocyte colony-stimulating factor (G-CSF) in previously treated patients with advanced NSCLC. A phase II study and review of the literature
17. Docetaxel (taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced NSCLC
18. Experience with new chemotherapeutic agents in non-small cell lung cancer
19. Prospective randomized trial of docetaxel versus best supportive care in patients with NSLCL previously treated with platinum-based chemotherapy
20. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: A preliminary report on an active regimen
21. Docetaxel and gemcitabine combinations in NSCLC
22. Docetaxel (taxotere) and gemcitabine: Phase I and early phase II studies: Results to date and an overview of ongoing studies
23. Interaction between cisplatin and gemcitabine in vitro and in vivo
24. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with NSCLC
25. Taxol in combination with doxorubicin or etoposide
26. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines
27. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines